Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SGN-EGFRd2 |
| Synonyms | |
| Therapy Description |
SGN-EGFRd2 is a bispecific gamma delta T-cell engager targeting EGFR and the Vdelta2 TCR expressed on Vgamma9Vdelta2 T-cells, which potentially induces an antitumor immune response (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SGN-EGFRd2 | SGN EGFRd2|SGNEGFRd2|LAVA1223|LAVA 1223|LAVA-1223 | EGFR Antibody 72 | SGN-EGFRd2 is a bispecific gamma delta T-cell engager targeting EGFR and the Vdelta2 TCR expressed on Vgamma9Vdelta2 T-cells, which potentially induces an antitumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05983133 | Phase I | SGN-EGFRd2 | A Study of SGN-EGFRd2 in Advanced Solid Tumors | Recruiting | USA | GBR | 0 |